Psoriasis: therapeutic aspects.
Some of the more common features of psoriasis are reviewed here as an introduction to therapeutic modalities that can be employed in the management of this disorder in the New Zealand situation. An approximate indication of costs for the various therapies is included. This article is sponsored by the therapeutics section of the Department of Health, however, the views of the contributors do not necessarily reflect departmental policies.
Young
D W
DW
Downey
D J
DJ
D000305:Adrenal Cortex Hormones / Q000191:economics / Q000627:therapeutic use; D000875:Anthralin / Q000191:economics / Q000627:therapeutic use; D003524:Cyclosporins / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D004643:Emollients / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007641:Keratolytic Agents / Q000191:economics / Q000627:therapeutic use; D008727:Methotrexate / Q000191:economics / Q000627:therapeutic use; D011701:PUVA Therapy / Q000191:economics / Q000592:standards; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D012176:Retinoids / Q000191:economics / Q000627:therapeutic use; D013638:Tars / Q000191:economics / Q000627:therapeutic use; D014467:Ultraviolet Therapy / Q000191:economics / Q000592:standards
D000305:Adrenal Cortex Hormones; D003524:Cyclosporins; D004643:Emollients; D007641:Keratolytic Agents; D012176:Retinoids; D013638:Tars; D000875:Anthralin; D008727:Methotrexate